Faculty profile

Mannix Auger-Messier

ResearcherPharmacologie - PhysiologieUniversité de Sherbrooke

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Sherbrooke directory, so their courses may be missing. Find their university profile.

Mannix Auger-Messier

Researcher

Pharmacologie - Physiologie

Health Sciences

Université de Sherbrooke

Sherbrooke, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
8 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 5 research grants (3 NSERC, 2 CIHR), most recently in 2019.
Supervised 2 trainees who won CIHR awards, most recently in 2018.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Animal Models Apelin Apj Receptor Biased Signaling Drug Discovery G Protein-Coupled Receptor Heart Failure Macrocycles

Latest papers

Tunable Biased Signaling of the Angiotensin II Type 1 Receptor for Inotropy via C-Terminal Peptide Engineering and Allosteric Site Targeting.
Journal of medicinal chemistry · 2026
ArfGAP with Dual Pleckstrin Homology Domains 2 Promotes Hypertrophy of Cultured Neonatal Cardiomyocytes.
International journal of molecular sciences · 2025 · senior author
A Metabolically Stable Apelin-13 Analog Acting as a Potent ITo Potassium Current Blocker with Potential Benefits for Brugada Syndrome.
International journal of molecular sciences · 2025

All 30 publications

Latest funding

Impact of novel ubiquitin-based Galphas regulation on receptor signaling and trafficking
CIHR · 2023 · Co-investigator
$1,009,800
Functional and structural understanding of angiotensin II type 1 receptor biased signaling.
CIHR · 2020 · Co-investigator
$1,189,576
Endosomal trafficking and functions in cardiomyocytes: insights from Arf6 signaling
NSERC · 2019 · Principal investigator
$192,000

All 12 grants and awards

30 publications.

Tunable Biased Signaling of the Angiotensin II Type 1 Receptor for Inotropy via C-Terminal Peptide Engineering and Allosteric Site Targeting.

Hadjadj M, Hassanzadeh M, Martel J, Roy MF, Giguère H, Murza A, Holleran BJ, Namkung Y, Froehlich U, Leduc R, Auger-Messier M, Laporte SA, Boudreault PL

Journal of medicinal chemistry2026

DOI: 10.1021/acs.jmedchem.5c01259 PMID: 41545027

ArfGAP with Dual Pleckstrin Homology Domains 2 Promotes Hypertrophy of Cultured Neonatal Cardiomyocytes.

Berthiaume J, Dumont AA, Dumont L, Roy MF, Giguère H, Auger-Messier M

International journal of molecular sciences2025Senior author

DOI: 10.3390/ijms26157588 PMID: 40806715

A Metabolically Stable Apelin-13 Analog Acting as a Potent ITo Potassium Current Blocker with Potential Benefits for Brugada Syndrome.

Contreras Vite JA, Tiffinger A, Théroux L, Morin N, Auger-Messier M, Boudreault PL, Sarret P, Lesur O, Dumaine R

International journal of molecular sciences2025

DOI: 10.3390/ijms26062735 PMID: 40141374

Apelin stimulation of the vascular skeletal muscle stem cell niche enhances endogenous repair in dystrophic mice.

Le Moal E, Liu Y, Collerette-Tremblay J, Dumontier S, Fabre P, Molina T, Dort J, Orfi Z, Denault N, Boutin J, Michaud J, Giguère H, Desroches A, Trân K, Ellezam B, Vézina F, Bedard S, Raynaud C, Balg F, Sarret P, Boudreault PL, Scott MS, Denault JB, Marsault E, Feige JN, Auger-Messier M, Dumont NA, Bentzinger CF

Science translational medicine2024

DOI: 10.1126/scitranslmed.abn8529 PMID: 38507466

Apelin prevents diabetes-induced poor collateral vessel formation and blood flow reperfusion in ischemic limb.

Robillard S, Trân K, Lachance MS, Brazeau T, Boisvert E, Lizotte F, Auger-Messier M, Boudreault PL, Marsault É, Geraldes P

Frontiers in cardiovascular medicine2023

DOI: 10.3389/fcvm.2023.1191891 PMID: 37636297

Chymase Inhibition Resolves and Prevents Deep Vein Thrombosis Without Increasing Bleeding Time in the Mouse Model.

Lapointe C, Vincent L, Giguère H, Auger-Messier M, Schwertani A, Jin D, Takai S, Pejler G, Sirois MG, Tinel H, Heitmeier S, D'Orléans-Juste P

Journal of the American Heart Association2023

DOI: 10.1161/jaha.122.028056 PMID: 36752268

Monitoring TRPC7 Conformational Changes by BRET Following GPCR Activation.

Pétigny C, Dumont AA, Giguère H, Collette A, Holleran BJ, Iftinca M, Altier C, Besserer-Offroy É, Auger-Messier M, Leduc R

International journal of molecular sciences2022

DOI: 10.3390/ijms23052502 PMID: 35269644

Size-Reduced Macrocyclic Analogues of [Pyr1]-apelin-13 Showing Negative Gα12 Bias Still Produce Prolonged Cardiac Effects.

Tran K, Sainsily X, Côté J, Coquerel D, Couvineau P, Saibi S, Haroune L, Besserer-Offroy É, Flynn-Robitaille J, Resua Rojas M, Murza A, Longpré JM, Auger-Messier M, Lesur O, Bouvier M, Marsault É, Boudreault PL, Sarret P

Journal of medicinal chemistry2022

DOI: 10.1021/acs.jmedchem.1c01708 PMID: 34982553

Apelin-13 in septic shock: effective in supporting hemodynamics in sheep but compromised by enzymatic breakdown in patients.

Coquerel D, Lamoureux J, Chagnon F, Trân K, Sage M, Fortin-Pellerin E, Delile E, Sainsily X, Fournier J, Dumont AA, Auger-Messier M, Sarret P, Marsault E, Praud JP, Fülöp T, Lesur O

Scientific reports2021

DOI: 10.1038/s41598-021-02087-4 PMID: 34815457

Elabela Protects Spontaneously Hypertensive Rats From Hypertension and Cardiorenal Dysfunctions Exacerbated by Dietary High-Salt Intake.

Sainsily X, Coquerel D, Giguère H, Dumont L, Tran K, Noll C, Ionescu AL, Côté J, Longpré JM, Carpentier A, Marsault É, Lesur O, Sarret P, Auger-Messier M

Frontiers in pharmacology2021Senior author

DOI: 10.3389/fphar.2021.709467 PMID: 34385922

Impact of novel ubiquitin-based Galphas regulation on receptor signaling and trafficking

Co-investigatorCIHR2023Project Grant

Principal investigators: Lavoie, Christine

Keywords: Endosomal Sorting; G Alpha S; G Protein Coupled Receptor (Gpcr); Heart-Cardiomyocytes; Heterotrimeric G Proteins; Intracellular Trafficking; Signal Transduction; Ubiquitin; Ubiquitin Interacting Motif (Uim)

$1,009,800

Functional and structural understanding of angiotensin II type 1 receptor biased signaling.

Co-investigatorCIHR2020Project Grant

Principal investigators: Laporte, Stéphane A; Leduc, Richard

Keywords: Angiotensin Ii Type 1 Receptor; Cardiac Diseases; Cell Signaling; Functional Selectivity; G Protein-Coupled Receptor (Gpcr); Peptide Chemistry; Protein Structure

$1,189,576

Endosomal trafficking and functions in cardiomyocytes: insights from Arf6 signaling

Principal investigatorNSERC2019Discovery Grants Program - Individual

Principal investigators: AugerMessier, Mannix

$192,000

Do bias signaling of the apelinergic receptor can improve the treatment of acute cardiovascular dysfunction and injury related to septic shock?

SupervisorCIHR2018CIHR Fellowship

Principal investigators: Coquerel, David

Keywords: Acute Heart Failure; Apelin Receptor; Bias Signaling; Cardiomyocytes; Sepsis

$90,000

Régulation par la MAPK p38 cardiaque sur la fonction d'épissage alternatif de SRSF3

SupervisorCIHR2018Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Principal investigators: Dumont, Audrey-Ann

Keywords: Cardiomyocytes; Insuffisance Cardiaque; Mapk P38; Rna-Seq; Spliceosome; Srsf3; Épissage Alternatif

$105,000

Exploiting ELABELA and analogues to Protect from Septic Shock

Co-investigatorCIHR2018Project Grant

Principal investigators: Lesur, Olivier J; Marsault, Eric

Keywords: Animal Models; Apelin Receptor; Apelins; Biased Signalling; Cardiovascular Dysfunction; Drug Discovery; Elabela; G Protein-Coupled Receptors; Renal Dysfunction; Septic Shock

$707,626

Journée Phare 2017

Co-investigatorCIHR2017Planning and Dissemination Grant - Institute Community Support

Principal investigators: Brouillette, Rebecca

Keywords: Biotechnologie; Cancer; Collaborations Interdisciplinaires; Immunologie; Neurosciences; Pharmacologie; Recherche Biomédicale; Santé Humaine; Vulgarisation Scientifique; Étudiants-Chercheurs

$10,000

Exploiting ELABELA and Analogues to Protect from Septic Shock

Co-investigatorCIHR2017Project Grant

Principal investigators: Lesur, Olivier J; Marsault, Eric

Keywords: Animal Models; Apelin Receptor; Apelins; Biased Signaling; Cardiovascular Dysfunction; Drug Discovery; Elabela; G Protein-Coupled Receptors; Kidney Dysfunction; Septic Shock

$100,000

The Apelin Receptor as a Target for Heart Failure

Principal investigatorCIHR2016Project Grant

Principal investigators: Marsault, Eric; Auger-Messier, Mannix

Keywords: Animal Models; Apelin; Apj Receptor; Biased Signaling; Drug Discovery; G Protein-Coupled Receptor; Heart Failure; Macrocycles; Molecular Dynamics; Peptidomimetic

$665,550

Propriétés de nouveaux analogues de l'apéline-13 sur la fonction cardiaque

Principal investigatorNSERC2015Engage Grants Program

Principal investigators: AugerMessier, Mannix

$25,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Mannix Auger-Messier

Research

Latest papers

Latest funding

Tunable Biased Signaling of the Angiotensin II Type 1 Receptor for Inotropy via C-Terminal Peptide Engineering and Allosteric Site Targeting.

ArfGAP with Dual Pleckstrin Homology Domains 2 Promotes Hypertrophy of Cultured Neonatal Cardiomyocytes.

A Metabolically Stable Apelin-13 Analog Acting as a Potent ITo Potassium Current Blocker with Potential Benefits for Brugada Syndrome.

Apelin stimulation of the vascular skeletal muscle stem cell niche enhances endogenous repair in dystrophic mice.

Apelin prevents diabetes-induced poor collateral vessel formation and blood flow reperfusion in ischemic limb.

Chymase Inhibition Resolves and Prevents Deep Vein Thrombosis Without Increasing Bleeding Time in the Mouse Model.

Monitoring TRPC7 Conformational Changes by BRET Following GPCR Activation.

Size-Reduced Macrocyclic Analogues of [Pyr1]-apelin-13 Showing Negative Gα12 Bias Still Produce Prolonged Cardiac Effects.

Apelin-13 in septic shock: effective in supporting hemodynamics in sheep but compromised by enzymatic breakdown in patients.

Elabela Protects Spontaneously Hypertensive Rats From Hypertension and Cardiorenal Dysfunctions Exacerbated by Dietary High-Salt Intake.

Impact of novel ubiquitin-based Galphas regulation on receptor signaling and trafficking

Functional and structural understanding of angiotensin II type 1 receptor biased signaling.

Endosomal trafficking and functions in cardiomyocytes: insights from Arf6 signaling

Do bias signaling of the apelinergic receptor can improve the treatment of acute cardiovascular dysfunction and injury related to septic shock?

Régulation par la MAPK p38 cardiaque sur la fonction d'épissage alternatif de SRSF3

Exploiting ELABELA and analogues to Protect from Septic Shock

Journée Phare 2017

Exploiting ELABELA and Analogues to Protect from Septic Shock

The Apelin Receptor as a Target for Heart Failure

Propriétés de nouveaux analogues de l'apéline-13 sur la fonction cardiaque

Frequent collaborators

Olivier Lesur

Philippe Sarret

Richard Leduc

Pierre-Luc Boudreault

Eric Marsault

Gaétan Guillemette

Pedro Geraldes

Jean-Luc Parent

Adel Schwertani

Mary-Ellen Harper

Jean-Bernard Denault

Étienne Fortin-Pellerin

Michel Bouvier

Christophe Altier

Jean-Paul Praud

Mannix Auger-Messier

Research

Latest papers

Latest funding

Tunable Biased Signaling of the Angiotensin II Type 1 Receptor for Inotropy via C-Terminal Peptide Engineering and Allosteric Site Targeting.

ArfGAP with Dual Pleckstrin Homology Domains 2 Promotes Hypertrophy of Cultured Neonatal Cardiomyocytes.

A Metabolically Stable Apelin-13 Analog Acting as a Potent ITo Potassium Current Blocker with Potential Benefits for Brugada Syndrome.

Apelin stimulation of the vascular skeletal muscle stem cell niche enhances endogenous repair in dystrophic mice.

Apelin prevents diabetes-induced poor collateral vessel formation and blood flow reperfusion in ischemic limb.

Chymase Inhibition Resolves and Prevents Deep Vein Thrombosis Without Increasing Bleeding Time in the Mouse Model.

Monitoring TRPC7 Conformational Changes by BRET Following GPCR Activation.

Size-Reduced Macrocyclic Analogues of [Pyr1]-apelin-13 Showing Negative G&#x3b1;12 Bias Still Produce Prolonged Cardiac Effects.

Apelin-13 in septic shock: effective in supporting hemodynamics in sheep but compromised by enzymatic breakdown in patients.

Elabela Protects Spontaneously Hypertensive Rats From Hypertension and Cardiorenal Dysfunctions Exacerbated by Dietary High-Salt Intake.

Endosomal trafficking and functions in cardiomyocytes: insights from Arf6 signaling

Propriétés de nouveaux analogues de l'apéline-13 sur la fonction cardiaque

Frequent collaborators

Olivier Lesur

Philippe Sarret

Richard Leduc

Pierre-Luc Boudreault

Eric Marsault

Gaétan Guillemette

Pedro Geraldes

Jean-Luc Parent

Adel Schwertani

Mary-Ellen Harper

Jean-Bernard Denault

Étienne Fortin-Pellerin

Michel Bouvier

Christophe Altier

Jean-Paul Praud

Size-Reduced Macrocyclic Analogues of [Pyr1]-apelin-13 Showing Negative Gα12 Bias Still Produce Prolonged Cardiac Effects.